Abstract 546P
Background
More than 70% of patients with T1 colorectal cancer (CRC) undergo a radical surgery involving lymph node dissection, despite the presence of lymph node metastasis (LNM) being observed in only ∼10% of cases. To reduce unnecessary radical surgery, we developed a multimodal artificial intelligence (AI) system to identify T1 CRC at risk for LNM.
Methods
We analyzed 402 CRC patients from two independent multicenter cohorts, including a training (n = 219) and a validation cohort (n = 183). Proteomics dataset from tumor tissue were identified and quantified using LC-MS/MS analysis. Multiple pathomics features were extracted from whole H&E slides with patch-level convolutional neural network training in weakly supervised manner. Clinicopathological characteristics included age, tumor size, location, lymphatic and vascular invasion, perineural invasion, histologic grade, and CEA. A machine-learning artificial neural network using proteomics, pathomics and clinicopathological features was developed.
Results
LNM were detected in 78 out of 219 patients (35.6%) within the training cohort and in 29 out of 183 patients (15.8%) within the validation cohort. A panel of six protein biomarkers (OSBPL5, ATAD2, BAIAP2, MANBA, ITPR2, ARHGAP5) screened by proteomics was quantified by immunohistochemistry and subsequently integrated into the AI system. In the validation cohort, the multimodal AI system achieved robust classification of LNM status, yielding an AUC of 0.978. In comparison, the guideline-based model exhibited an AUC of 0.717 for identifying LNM (P < 0.001).
Conclusions
The AI system integrating deep learning-proteomics, pathomics and clinicopathological features robustly identifies T1 CRC patients at risk of LNM in a preoperative setting. The multimodal AI system would improve clinical practice by alleviating the burden of unnecessary overtreatment for T1 CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jianmin Xu.
Funding
The National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
532P - G-CSF secondary prophylaxis in patients (pts) with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI): The GERCOR LONGBOARD study
Presenter: Jean-Baptiste Bachet
Session: Poster session 15
533P - First-line treatment in older patients with metastatic colorectal cancer: A large real-world study
Presenter: debora basile
Session: Poster session 15
534P - Second-line treatment in older patients with metastatic colorectal cancer: The ELECTRA study
Presenter: Alessia Cordua
Session: Poster session 15
535P - Safety and efficacy of first-line immune checkpoint inhibitors in elderly colorectal cancer patients: An Italian real-world multicenter experience
Presenter: Alessandra Boccaccino
Session: Poster session 15
536P - A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: Long-term results of JCOG0603
Presenter: Yukihide Kanemitsu
Session: Poster session 15
537P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 15
538P - Combined hepatectomy with complete cytoreduction (CCS) and hyperthermic intraperitoneal chemotherapy (HIPEC) vs. HIPEC alone for metastatic colorectal cancer: A systematic review and meta-analysis
Presenter: Gabriele Lech
Session: Poster session 15
540P - Early treatment discontinuation (ETD) in dMMR/MSI-H metastastic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs)
Presenter: Julien Taieb
Session: Poster session 15
541P - Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW
Presenter: Thierry André
Session: Poster session 15